Trial Profile

A Phase I, Open-label, Multicenter, Dose-Escalating Study to Evaluate the Safety and Tolerability of KH631 Gene Therapy in Participants With Neovascular Age-related Macular Degeneration

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 28 Feb 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

20 Nov 2023 According to a Chengdu Origen Biotechnology Co Ltd media release, Jeffrey S.Heier, MD, director of the Vitreoretinal Service and Director of Retina Research at Ophthalmic Consultants of Boston and Avner Ingerman, MD, Chief Medical Officer of Vanotech are the principal investigators of this phase 1 study.
20 Nov 2023 According to a Chengdu Origen Biotechnology Co Ltd media release, company announced today the first patient dosed in the VAN-2201 multi-center Phase 1 clinical trial evaluating treatment with KH631 for patients with wet Age-related Macular Degeneration (wet AMD).
17 Aug 2023 Planned End Date changed from 1 May 2027 to 1 Sep 2027.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com